ATN-161

• UNSPSC Description:

  ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model.

• Target Antigen:

  Integrin

• Type:

  Reference compound

• Related Pathways:

  Cytoskeleton

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/atn-161.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N)C[C@@H](C(N)=O)NC([C@H](CS)NC([C@H](CO)NC([C@H](CC1=CNC=N1)NC([C@H]2N(C(C)=O)CCC2)=O)=O)=O)=O

• Molecular Weight:

  597.64

• References & Citations:

  [1]Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20;104(4):496-503.|[2]Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7213-20.Cancer Cell. 2019 Jan 14;35(1):64-80.e7. |Sci Signal. 2022 Dec 6;15(763):eabn2743.|Acs Biomater Sci Eng. 2023 Apr 24.|Cell Prolif. 2021 Apr;54(4):e13012.|Colloids Surf B Biointerfaces. 20 November 2021, 112227.|Stem Cell Res Ther. 2022 Jul 18;13(1):327.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 2

• CAS Number:

  262438-43-7